The global non-opioid pain patches market accounted for USD 3.50 billion in 2023 and is expected to reach at USD 5.50 billion by 2034 with a CAGR of 4.19% during the forecast period 2024-2034. Rising burden of pain-related illnesses, increased efforts in developing non-opioid patches, growing prevalence of chronic conditions such as cardiovascular disease, autoimmune disorders, diabetes, & arthritis, surge in research activities, governments are increasingly promoting awareness about innovative non-opioid heat patches, growing elderly population, market players & educational institutions are collaborating more to introduce novel products, and increasing approvals of non-narcotic pain patches from regulatory bodies are some of the key factors boosting the market growth.
Increasing approvals of non-narcotic pain patches from regulatory bodies is predicted to boost the market growth during the forecast period. For instance, in August 2022, Scilex Holding Company, a commercial biopharmaceutical firm specializing in non-opioid treatments for both acute and chronic pain sufferers, has obtained fast-track designation for its investigative product, SP-103, which combines drug and device components. SP-103 is being developed as a potent non-opioid lidocaine topical system to address acute lower back pain. Approval of SP-103 could mark the inaugural FDA endorsement for a lidocaine topical product targeting acute lower back pain.
By patch type, lidocaine patches was the highest revenue-grossing segment in the global non-opioid pain patches market in 2023 owing to the increase in pain prevalence, rising number of clinical trials underway to showcase the effectiveness of lidocaine patches in managing postoperative pain, and surge in product launches by key market players. For instance, in June 2022, Hisamitsu America, a branch of Hisamitsu Pharmaceutical Co., Inc., which produces the Salonpas range of pain relief items, announced the release of the Salonpas Pain Relieving FLEX Patch Lidocaine 4%. This product incorporates advanced patch technology, offering a thin, flexible, and strongly adhesive solution. Additionally, ketoprofen patches is predicted to grow at the fastest CAGR during the forecast period owing to the surge in research & development of non-opioid pain patches and growing focus on the development of novel products.
By distribution channel, online pharmacies was the highest revenue-grossing segment in the global non-opioid pain patches market in 2023 owing to the online pharmacies are increasingly offering non-narcotic pain patches tailored for chronic pain conditions, particularly suitable for the elderly, and increase in the introduction of new products. For instance, in January 2023, Yaral Pharma Inc., the US-based generics arm of IBSA, an established multinational pharmaceutical firm, has introduced diclofenac epolamine topical system 1.3%. This product is the authorized generic version of IBSA Pharma's Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescribed nonsteroidal anti-inflammatory (NSAID) patch designed for the topical management of acute pain resulting from minor strains, sprains, and contusions. Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the occurrence of pain-related illnesses, surge in the number of patients grappling with chronic diseases, and heightened demand for innovative products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of pain-related diseases, expanding geriatric demographic, increase in cancer diagnoses, and surge in the introduction of new products. For instance, in February 2022, NEXGEL, Inc., known for its gentle, high-water-content hydrogel offerings for healthcare and consumer uses, has unveiled its MEDAGEL Bug Bite Relief Patch. Crafted in the USA with NEXGEL's calming hydrogel innovation, these cooling patches offer immediate relief for skin irritations resulting from insect bites. Additionally, Middle East & Africa region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the research & development of non-opioid patches, growing prevalence of chronic diseases, and increasing collaborations among market players & educational institutions to introduce innovative non-narcotic pain patches. For instance, in March 2023, Scilex Holding Company, a forward-thinking firm with a focus on procuring, developing, and marketing non-opioid pain relief solutions, has announced a distribution agreement for ZTlido in the Middle East and North Africa. The agreement includes a minimum purchase commitment of USD 105 million over a period of five years. ZTlido is a lidocaine topical system approved for alleviating neuropathic pain linked to postherpetic neuralgia (PHN).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing approvals of non-narcotic pain patches from regulatory bodies is predicted to boost the market growth during the forecast period. For instance, in August 2022, Scilex Holding Company, a commercial biopharmaceutical firm specializing in non-opioid treatments for both acute and chronic pain sufferers, has obtained fast-track designation for its investigative product, SP-103, which combines drug and device components. SP-103 is being developed as a potent non-opioid lidocaine topical system to address acute lower back pain. Approval of SP-103 could mark the inaugural FDA endorsement for a lidocaine topical product targeting acute lower back pain.
By patch type, lidocaine patches was the highest revenue-grossing segment in the global non-opioid pain patches market in 2023 owing to the increase in pain prevalence, rising number of clinical trials underway to showcase the effectiveness of lidocaine patches in managing postoperative pain, and surge in product launches by key market players. For instance, in June 2022, Hisamitsu America, a branch of Hisamitsu Pharmaceutical Co., Inc., which produces the Salonpas range of pain relief items, announced the release of the Salonpas Pain Relieving FLEX Patch Lidocaine 4%. This product incorporates advanced patch technology, offering a thin, flexible, and strongly adhesive solution. Additionally, ketoprofen patches is predicted to grow at the fastest CAGR during the forecast period owing to the surge in research & development of non-opioid pain patches and growing focus on the development of novel products.
By distribution channel, online pharmacies was the highest revenue-grossing segment in the global non-opioid pain patches market in 2023 owing to the online pharmacies are increasingly offering non-narcotic pain patches tailored for chronic pain conditions, particularly suitable for the elderly, and increase in the introduction of new products. For instance, in January 2023, Yaral Pharma Inc., the US-based generics arm of IBSA, an established multinational pharmaceutical firm, has introduced diclofenac epolamine topical system 1.3%. This product is the authorized generic version of IBSA Pharma's Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescribed nonsteroidal anti-inflammatory (NSAID) patch designed for the topical management of acute pain resulting from minor strains, sprains, and contusions. Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the occurrence of pain-related illnesses, surge in the number of patients grappling with chronic diseases, and heightened demand for innovative products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of pain-related diseases, expanding geriatric demographic, increase in cancer diagnoses, and surge in the introduction of new products. For instance, in February 2022, NEXGEL, Inc., known for its gentle, high-water-content hydrogel offerings for healthcare and consumer uses, has unveiled its MEDAGEL Bug Bite Relief Patch. Crafted in the USA with NEXGEL's calming hydrogel innovation, these cooling patches offer immediate relief for skin irritations resulting from insect bites. Additionally, Middle East & Africa region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the research & development of non-opioid patches, growing prevalence of chronic diseases, and increasing collaborations among market players & educational institutions to introduce innovative non-narcotic pain patches. For instance, in March 2023, Scilex Holding Company, a forward-thinking firm with a focus on procuring, developing, and marketing non-opioid pain relief solutions, has announced a distribution agreement for ZTlido in the Middle East and North Africa. The agreement includes a minimum purchase commitment of USD 105 million over a period of five years. ZTlido is a lidocaine topical system approved for alleviating neuropathic pain linked to postherpetic neuralgia (PHN).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Patch Type and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Non-opioid Pain Patches Market Report 2023 - 2034
Non-opioid Pain Patches Market Analysis & Forecast by Patch Type 2023 - 2034 (Revenue USD Bn)
- Capsaicin Patches
- Lidocaine Patches
- Ketoprofen Patches
- Diclofenac Patches
- Others
Non-opioid Pain Patches Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Others
Non-opioid Pain Patches Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Non-opioid Pain Patches Market: Patch Type Estimates & Trend Analysis
8. Non-opioid Pain Patches Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Non-opioid Pain Patches Market
11. Europe Global Non-opioid Pain Patches Market
12. Asia Pacific Global Non-opioid Pain Patches Market
13. Latin America Global Non-opioid Pain Patches Market
14. MEA Global Non-opioid Pain Patches Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Sorrento Therapeutics (SCILEX Pharmaceuticals)
- Hisamitsu Pharmaceutical Co. Inc.
- Veridian Healthcare
- Sanofi
- Teikoku Seiyaku Co. Ltd.
- Averitas Pharma
- Endo Pharmaceuticals Inc.
- Sparsha Pharma International Pvt Ltd
- Teva Pharmaceuticals Industries Ltd.
- TEH SENG Pharmaceutical Mfg. Co. Ltd
